Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC69H63N7O14 |
InChIKeyXWGYUGFXKPAXLC-UHFFFAOYSA-N |
CAS Registry1451741-62-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 31 Oct 2022 |